ESC Leads Key Work Packages in €27 M EuroHeartPath Project to Redesign Cardiovascular Care Across 15 EU States

ESC Leads Key Work Packages in €27 M EuroHeartPath Project to Redesign Cardiovascular Care Across 15 EU States

(IN BRIEF) From its leadership of key work packages to its rich data resources—the ESC Atlas of Cardiology and GRASP study—the European Society of Cardiology is driving EuroHeartPath’s mission to transform heart-disease care in Europe. This €27 million Horizon Europe IHI-JU project will execute 18 pathfinder studies in AI & machine learning, digital health, point-of-care testing and robotics across 15 countries. By mapping and comparing care pathways and embedding equity and patient-centredness, EuroHeartPath aims to redesign prevention, diagnosis, monitoring and treatment, ensuring innovations rapidly translate into improved outcomes and resilient health systems.

(PRESS RELEASE) UTRECHT, 17-Jun-2025 — /EuropaWire/ — The European Society of Cardiology (ESC) is proud to join the EuroHeartPath consortium, a landmark €27 million, five-year initiative under the Horizon Europe Innovative Health Initiative Joint Undertaking (IHI-JU), launched on 16 June 2025 in Utrecht. EuroHeartPath unites 35 academic, clinical, public-health, industry and patient-advocacy partners from 15 EU countries to systematically analyse and optimise cardiovascular care pathways—from prevention and early detection through advanced treatment.

As a co-leader of multiple work packages, the ESC brings its decade-long expertise in multinational data collection via the ESC Atlas of Cardiology and the GRASP longitudinal study. In WP2, we are spearheading protocol development and rigorous data gathering to map existing care models. In WP3 and WP4, we integrate pathway elements and apply insights from the GRASP program—tracking 6,000 patients across 30 sites—to enhance genetic testing, improve adherence, and refine clinical guidelines for cardiomyopathies and myocarditis. Through WP6 and WP8, the ESC shapes policy recommendations and market-needs assessments, ensuring sustainable healthcare models. Leading WP9, we drive communication and dissemination to guarantee EuroHeartPath’s innovations reach clinicians, patients and policymakers.

EuroHeartPath comprises 18 cutting-edge “pathfinder” studies across four technological pillars:

• AI & Machine Learning: For example, the EXPLAIN pathfinder enhances ECG interpretation beyond current computerized limits.
• Digital Health Integration: Enabling seamless telemonitoring and interoperable health records.
• Point-of-Care Testing: Deploying rapid biomarker assays to expedite diagnosis and treatment decisions.
• Technology & Robotics: Advancing robotic systems for precise interventions and rehabilitation support.

Another exemplar, PACEVALUE, addresses critical gaps in managing cardiovascular implantable electronic devices for arrhythmias and heart failure. Throughout every study, the ESC champions patient centredness and equity, devoting special attention to underserved communities and personalised, value-based care.

Notes to editor

Contact:  

ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow us on X @ESCardioNews

About the European Society of Cardiology 

The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About EuroHeartPath

Funded by the Innovative Health Initiative Joint Undertaking (IHI-JU), EuroHeartPath unites prominent stakeholders including UMC Utrecht, Amsterdam UMC, London School of Economics and Political Science, Technische Universiteit Eindhoven, Deutsches Herzzentrum München, Insel Gruppe AG (University Hospital Bern), Servicio Madrileño de Salud (SERMAS), Assistance Publique Hôpitaux de Paris (APHP), RCF@ICPS, Charité – Universitätsmedizin Berlin, Universiteit Maastricht, Philips Medical Systems Nederland BV, Philips France Commercial, Medtronic Ibérica SA, Medtronic GmbH, AstraZeneca UK Limited, Boston Scientific Netherlands BV, IQVIA Solutions Belgium BV, Novo Nordisk A/S, Novartis Pharma BV, Amarin Pharmaceuticals Ireland Limited, Vintura BV, Zeesta Labs, Corbotics BV, Chateau Sante, Van Vliet Diagnostics BV, Cordys Analytics, Viduet Health B.V, Stichting Cardiologie Centra Nederland, Heart for Health ICT BV, Cito Diagnostics BV, Discovery XD One SRL, Stichting WONCA Europe, European Society of Cardiology (ESC), European Pathway Association (EPA), Outcomes’10 SL, European Public Health Association (EUPHA). The initiative spans multiple European countries, aiming to set new standards in cardiovascular care.

SOURCE: European Society of Cardiology